Loading...
Loading...
ACAD| Name | Value |
|---|---|
| Revenues | 118.5M |
| Cost of Revenue | 1.7M |
| Gross Profit | 116.8M |
| Operating Expense | 170.4M |
| Operating I/L | -53.6M |
| Other Income/Expense | 8.6M |
| Interest Income | 3.8M |
| Pretax | -44.9M |
| Income Tax Expense | -1.9M |
| Net Income/Loss | -43.0M |
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development and commercialization of small molecule drugs for central nervous system disorders. Its flagship product, NUPLAZID (pimavanserin), targets hallucinations and delusions associated with Parkinson's disease psychosis. The company's pipeline includes pimavanserin for Alzheimer's disease psychosis and negative symptoms of schizophrenia, Trofinetide for Rett syndrome, ACP-044 for acute and chronic pain, and ACP-319 for schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. generates revenue through the sale of its pharmaceutical products and the ongoing development of its pipeline.
